Tobias Meyer elected to the American Academy of Arts and Sciences

Meyer is the Joseph C. Hinsey Professor in Cell and Developmental Biology at Weill Cornell Medicine.

HIV patients fare well with mpox treatment

Patients with HIV had similar treatment outcomes to patients without HIV when treated for mpox with an antiviral drug called tecovirimat, according to a new study.

Engineering, Weill Cornell Medicine pilot M.D.-M.Eng. degree

As part of a new cross-college initiative designed to accelerate engineering innovations in medicine, Cornell Engineering is piloting an M.D.-M.Eng. program that allows medical students at Weill Cornell Medicine to earn a one-year professional Master of Engineering degree.

Around Cornell

Epigenetic drug aids chemotherapy in lymphoma study

Nearly 90% of patients with an aggressive subtype of non-Hodgkin lymphoma had their cancer go into remission in a small phase 2 clinical trial testing a treatment aimed at making chemotherapy more effective, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.

Weill Cornell Medicine celebrates two landmark anniversaries

Weill Cornell Medicine commemorates 125 years since its founding, and 25 years since its renaming.

Incubator to support projects for work and social change

The Yang-Tan WorkABILITY Incubator, recently launched through the ILR School’s Center for Applied Research on Work, will support innovative applied research projects and collaborations.

Interfering with antiviral pathway may deter Alzheimer’s

Targeting part of a key antiviral pathway may one day offer a new therapeutic approach to deterring or delaying cognitive decline, according to preclinical research led by Weill Cornell Medicine scientists.

Circumstances influence happiness as much as personality

Happiness can’t be bought, but nor does it depend mostly on one’s mindset, as many happiness surveys would suggest, according to a recent study by Cornell psychology researchers.

Trial shows strong COVID protection in antibody combination

A treatment combining two antibodies against the coronavirus SARS-CoV-2 strongly protected high-risk people with early COVID-19 symptoms from hospitalization and death in an international Phase 2/3 clinical trial.